Last reviewed · How we verify
Anlotinib hydrochloride capsules
Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases.
Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases. Used for Advanced non-small cell lung cancer, Soft tissue sarcoma, Medullary thyroid cancer.
At a glance
| Generic name | Anlotinib hydrochloride capsules |
|---|---|
| Also known as | Fukewei, YBH00802018, AHC |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Multi-targeted tyrosine kinase inhibitor |
| Target | VEGFR, FGFR, PDGFR, c-Kit, RET |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Anlotinib hydrochloride inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and growth, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR). By blocking these pathways, it suppresses new blood vessel formation that tumors depend on for growth and metastasis, thereby inhibiting tumor progression.
Approved indications
- Advanced non-small cell lung cancer
- Soft tissue sarcoma
- Medullary thyroid cancer
Common side effects
- Hypertension
- Proteinuria
- Hand-foot skin reaction
- Fatigue
- Diarrhea
- Anorexia
- Nausea
Key clinical trials
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma (PHASE3)
- Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers (PHASE1)
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (PHASE3)
- Anlotinib Capsules in the Treatment for IPF/PF-ILDs (PHASE2, PHASE3)
- Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma (PHASE3)
- A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer (PHASE3)
- Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: